Duane C. Hassane, Ph.D.

2002 University of Kentucky, Lexington, KY 
Microbiology Biology
"Duane Hassane"


Sign in to add mentor
Carol Pickett grad student 2002 University of Kentucky
 (Campylobacter jejuni cytolethal distending toxin: The effects of the CDTB subunit on eukaryotic cells.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Li S, Garrett-Bakelman FE, Chung SS, et al. (2016) Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine
Hassane DC, Guzman ML. (2015) Targeting leukemia stem cells Targeted Therapy of Acute Myeloid Leukemi. 573-590
Guzman ML, Yang N, Sharma KK, et al. (2014) Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90
Sen S, Hassane DC, Corbett C, et al. (2013) Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental Hematology. 41: 799-807.e4
Sampson ER, McMurray HR, Hassane DC, et al. (2013) Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 32: 3809-18
Felipe Rico J, Hassane DC, Guzman ML. (2013) Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Letters. 338: 4-9
Ashton JM, Balys M, Neering SJ, et al. (2012) Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 11: 359-72
Hassane DC, Sen S, Minhajuddin M, et al. (2010) Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 116: 5983-90
Hassane DC, Guzman ML, Corbett C, et al. (2008) Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111: 5654-62
Guzman ML, Rossi RM, Neelakantan S, et al. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 110: 4427-35
See more...